Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

England's NICE rebuffs Pfizer and Astellas' Xtandi in nonmetastatic prostate cancer

fiercepharmaApril 09, 2019

Tag: Pfizer , England , NICE rebuffs

PharmaSources Customer Service